The Filings Report

Elanco Animal Health Incorporated Common Stock

ELANNYSECIK 1739104Healthcare / Drug Manufacturersfiscal year ends December38 quarters since 2017

Revenue, Q2 FY2026
$1.4B
+10.2% on Q2 FY2025
Net income
$54M
+390.9% on Q2 FY2025
Free cash flow
$244M
+35.6% on Q2 FY2025
Diluted EPS
$0.11
+450.0% on Q2 FY2025
Revenue, TTM
$5.0B
trailing four quarters
Net margin, TTM
-4.0%
net income −$199M
Free cash flow, TTM
$379M
$617M less $238M capex
Cash and equivalents
$530M
long-term debt $3.7B, Jun 30, 2026
Shares, 12-month change
+0.6%
500M shares, Jun 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$12.0B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 5, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Elanco Animal Health Incorporated Common Stock reported revenue of $1.4B, +10.2% on Q2 FY2025, and net income of $54M (+390.9%). Free cash flow, operating cash flow less capital expenditures, was $244M ($277M less $33M). Diluted earnings per share were $0.11.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 5, 2026.

Revenue and net incomeRevenueNet income
−$2B−$1B$0$1B$2BQ3'22, Revenue: $1.0BQ3'22, Net income: −$65MQ3'22Q4'22, Revenue: $985MQ4'22, Net income: −$54MQ4'22Q1'23, Revenue: $1.3BQ1'23, Net income: $103MQ1'23Q2'23, Revenue: $1.1BQ2'23, Net income: −$97MQ2'23Q3'23, Revenue: $1.1BQ3'23, Net income: −$1.1BQ3'23Q4'23, Revenue: $1.0BQ4'23, Net income: −$141MQ4'23Q1'24, Revenue: $1.2BQ1'24, Net income: $32MQ1'24Q2'24, Revenue: $1.2BQ2'24, Net income: −$50MQ2'24Q3'24, Revenue: $1.0BQ3'24, Net income: $364MQ3'24Q4'24, Revenue: $1.0BQ4'24, Net income: −$8MQ4'24Q1'25, Revenue: $1.2BQ1'25, Net income: $67MQ1'25Q2'25, Revenue: $1.2BQ2'25, Net income: $11MQ2'25Q3'25, Revenue: $1.1BQ3'25, Net income: −$34MQ3'25Q4'25, Revenue: $1.1BQ4'25, Net income: −$276MQ4'25Q1'26, Revenue: $1.4BQ1'26, Net income: $57MQ1'26Q2'26, Revenue: $1.4BQ2'26, Net income: $54MQ2'26−$2B−$1B$0$1B$2BQ3'22, Revenue: $1.0BQ3'22, Net income: −$65MQ4'22, Revenue: $985MQ4'22, Net income: −$54MQ4'22Q1'23, Revenue: $1.3BQ1'23, Net income: $103MQ2'23, Revenue: $1.1BQ2'23, Net income: −$97MQ2'23Q3'23, Revenue: $1.1BQ3'23, Net income: −$1.1BQ4'23, Revenue: $1.0BQ4'23, Net income: −$141MQ4'23Q1'24, Revenue: $1.2BQ1'24, Net income: $32MQ2'24, Revenue: $1.2BQ2'24, Net income: −$50MQ2'24Q3'24, Revenue: $1.0BQ3'24, Net income: $364MQ4'24, Revenue: $1.0BQ4'24, Net income: −$8MQ4'24Q1'25, Revenue: $1.2BQ1'25, Net income: $67MQ2'25, Revenue: $1.2BQ2'25, Net income: $11MQ2'25Q3'25, Revenue: $1.1BQ3'25, Net income: −$34MQ4'25, Revenue: $1.1BQ4'25, Net income: −$276MQ4'25Q1'26, Revenue: $1.4BQ1'26, Net income: $57MQ2'26, Revenue: $1.4BQ2'26, Net income: $54MQ2'26

Net income losses drawn in red.

Free cash flow
−$200M$0$200M$400MQ3'22, Free cash flow: $163MQ3'22Q4'22, Free cash flow: −$87MQ4'22Q1'23, Free cash flow: −$169MQ1'23Q2'23, Free cash flow: $19MQ2'23Q3'23, Free cash flow: $165MQ3'23Q4'23, Free cash flow: $116MQ4'23Q1'24, Free cash flow: −$22MQ1'24Q2'24, Free cash flow: $166MQ2'24Q3'24, Free cash flow: $120MQ3'24Q4'24, Free cash flow: $130MQ4'24Q1'25, Free cash flow: −$69MQ1'25Q2'25, Free cash flow: $180MQ2'25Q3'25, Free cash flow: $127MQ3'25Q4'25, Free cash flow: $46MQ4'25Q1'26, Free cash flow: −$38MQ1'26Q2'26, Free cash flow: $244MQ2'26−$200M$0$200M$400MQ3'22, Free cash flow: $163MQ4'22, Free cash flow: −$87MQ4'22Q1'23, Free cash flow: −$169MQ2'23, Free cash flow: $19MQ2'23Q3'23, Free cash flow: $165MQ4'23, Free cash flow: $116MQ4'23Q1'24, Free cash flow: −$22MQ2'24, Free cash flow: $166MQ2'24Q3'24, Free cash flow: $120MQ4'24, Free cash flow: $130MQ4'24Q1'25, Free cash flow: −$69MQ2'25, Free cash flow: $180MQ2'25Q3'25, Free cash flow: $127MQ4'25, Free cash flow: $46MQ4'25Q1'26, Free cash flow: −$38MQ2'26, Free cash flow: $244MQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$2B$4B$6B$8BQ3'22, Cash and equivalents: $460MQ3'22, Long-term debt: $5.5BQ3'22Q4'22, Cash and equivalents: $345MQ4'22, Long-term debt: $5.4BQ4'22Q1'23, Cash and equivalents: $318MQ1'23, Long-term debt: $5.6BQ1'23Q2'23, Cash and equivalents: $367MQ2'23, Long-term debt: $6.0BQ2'23Q3'23, Cash and equivalents: $369MQ3'23, Long-term debt: $5.9BQ3'23Q4'23, Cash and equivalents: $352MQ4'23, Long-term debt: $5.7BQ4'23Q1'24, Cash and equivalents: $345MQ1'24, Long-term debt: $5.7BQ1'24Q2'24, Cash and equivalents: $416MQ2'24, Long-term debt: $4.3BQ2'24Q3'24, Cash and equivalents: $490MQ3'24, Long-term debt: $4.3BQ3'24Q4'24, Cash and equivalents: $468MQ4'24, Long-term debt: $4.3BQ4'24Q1'25, Cash and equivalents: $487MQ1'25, Long-term debt: $4.4BQ1'25Q2'25, Cash and equivalents: $539MQ2'25, Long-term debt: $4.0BQ2'25Q3'25, Cash and equivalents: $505MQ3'25, Long-term debt: $3.8BQ3'25Q4'25, Cash and equivalents: $545MQ4'25, Long-term debt: $3.8BQ4'25Q1'26, Cash and equivalents: $428MQ1'26, Long-term debt: $3.7BQ1'26Q2'26, Cash and equivalents: $530MQ2'26, Long-term debt: $3.7BQ2'26$0$2B$4B$6B$8BQ3'22, Cash and equivalents: $460MQ3'22, Long-term debt: $5.5BQ4'22, Cash and equivalents: $345MQ4'22, Long-term debt: $5.4BQ4'22Q1'23, Cash and equivalents: $318MQ1'23, Long-term debt: $5.6BQ2'23, Cash and equivalents: $367MQ2'23, Long-term debt: $6.0BQ2'23Q3'23, Cash and equivalents: $369MQ3'23, Long-term debt: $5.9BQ4'23, Cash and equivalents: $352MQ4'23, Long-term debt: $5.7BQ4'23Q1'24, Cash and equivalents: $345MQ1'24, Long-term debt: $5.7BQ2'24, Cash and equivalents: $416MQ2'24, Long-term debt: $4.3BQ2'24Q3'24, Cash and equivalents: $490MQ3'24, Long-term debt: $4.3BQ4'24, Cash and equivalents: $468MQ4'24, Long-term debt: $4.3BQ4'24Q1'25, Cash and equivalents: $487MQ1'25, Long-term debt: $4.4BQ2'25, Cash and equivalents: $539MQ2'25, Long-term debt: $4.0BQ2'25Q3'25, Cash and equivalents: $505MQ3'25, Long-term debt: $3.8BQ4'25, Cash and equivalents: $545MQ4'25, Long-term debt: $3.8BQ4'25Q1'26, Cash and equivalents: $428MQ1'26, Long-term debt: $3.7BQ2'26, Cash and equivalents: $530MQ2'26, Long-term debt: $3.7BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Elanco Animal Health Incorporated Common Stock income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 25, 2025Q3 FY2024ended Sep 30, 2024filed Nov 7, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue1,3681,3711,1441,1371,2411,1931,0201,030+10.2%
Cost of revenue570586555530528509501492+8.0%
Gross profit798785589607713684519538+11.9%
Research and development92979389929481870.0%
Selling, general and administrative449381338351400341300323+12.3%
Operating income—————————
Other income (expense)———————(1)—
Pretax income5687(259)(50)2560(51)559+124.0%
Income tax23017(16)14(7)(43)195−85.7%
Net income5457(276)(34)1167(8)364+390.9%
Diluted EPS ($)0.110.11—(0.07)0.020.13—0.73+450.0%
Diluted shares (millions)506506—497500499—498—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Elanco Animal Health Incorporated Common Stock balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 25, 2025Q3 FY2024ended Sep 30, 2024filed Nov 7, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents530428545505539487468490−1.7%
Short-term investments—————————
Total current assets3,7973,5843,4583,4933,6143,4403,2153,366+5.1%
Total assets13,56113,22213,35813,55113,74212,94112,61413,283−1.3%
Total current liabilities1,8521,6621,5971,4551,3921,2691,3151,321+33.0%
Long-term debt3,6633,7363,7623,7693,9544,3514,3214,313−7.4%
Total liabilities6,9736,7226,8116,8026,9676,5886,5186,760+0.1%
Stockholders’ equity6,5886,5006,5476,7496,7756,3536,0966,523−2.8%
Shares outstanding (millions)500499497497497497495494—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Elanco Animal Health Incorporated Common Stock cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 25, 2025Q3 FY2024ended Sep 30, 2024filed Nov 7, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow27713108219237(4)177162+16.9%
Capital expenditures3351629257654742−42.1%
Free cash flow (CFO − capex)244(38)46127180(69)130120+35.6%
Depreciation and amortization171172174176169161164170+1.2%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 24, 2026.

Income statement

Elanco Animal Health Incorporated Common Stock income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 25, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Mar 1, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 1, 2021FY2019ended Dec 31, 2019filed Feb 28, 2020FY2018ended Dec 31, 2018filed Feb 20, 2019FY2017ended Dec 31, 2017filed Nov 8, 2018FY2016ended Dec 31, 2016filed Nov 8, 2018
Revenue4,7154,4394,4174,4114,7643,2733,0713,0672,8892,914
Cost of revenue2,1222,0031,9311,9132,1321,6671,4701,5741,4941,409
Gross profit2,5932,4362,486———————
Research and development368344327321369329270247252266
Selling, general and administrative1,4301,3141,2851,2651,403997760735780785
Operating income——————————
Other income (expense)——(75)(32)(5)178(28)(41)03
Pretax income(224)488(1,195)(72)(571)(677)78114(233)(22)
Income tax8150366(88)(103)10287826
Net income(232)338(1,231)(78)(483)(574)6887(311)(48)
Diluted EPS ($)(0.47)0.68(2.50)(0.16)(0.99)(1.30)0.180.28(1.06)—
Diluted shares (millions)496497492488487441370314293—

Balance sheet

Elanco Animal Health Incorporated Common Stock balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 25, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Mar 1, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 1, 2021FY2019ended Dec 31, 2019filed Feb 28, 2020FY2018ended Dec 31, 2018filed Feb 20, 2019FY2017ended Dec 31, 2017filed Nov 8, 2018FY2016ended Dec 31, 2016filed Nov 8, 2018
Cash and equivalents545468352345638495334475323—
Short-term investments——————————
Total current assets3,4583,2153,4073,2793,2743,4172,3732,5052,124—
Total assets13,35812,61414,36215,49116,47817,6938,9868,9578,940—
Total current liabilities1,5971,3151,2411,7021,6472,077819971643—
Long-term debt3,7624,3215,7365,4486,0255,5722,3312,4430—
Total liabilities6,8116,5188,1398,2028,9709,2173,4393,7591,160—
Stockholders’ equity6,5476,0966,2237,2897,5088,4575,5435,1977,7807,017
Shares outstanding (millions)497495493492473472399366——

Cash flow statement

Elanco Animal Health Incorporated Common Stock cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 25, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Mar 1, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 1, 2021FY2019ended Dec 31, 2019filed Feb 28, 2020FY2018ended Dec 31, 2018filed Feb 20, 2019FY2017ended Dec 31, 2017filed Nov 8, 2018FY2016ended Dec 31, 2016filed Nov 8, 2018
Operating cash flow560541271452483(41)224487174156
Capital expenditures27614714017115913514013599110
Free cash flow (CFO − capex)284394131281324(176)843537546
Depreciation and amortization680662694682716517314296318254
Share repurchases——————————
Dividends paid——————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 3, 2024 to November 3, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$1M
5 purchases by 5 insiders; officers and directors $1M
Sold, three months
$100K
1 sales by 1 insider; officers and directors $100K
Bought, twelve months
$3M
11 purchases by 7 insiders; officers and directors $3M
Sold, twelve months
$100K
1 sales by 1 insider; officers and directors $100K

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 15, 2026Bettington Timothy JSEE REMARKSopen-market sale10b5-14,350$23.00$100K138,911Oct 19, 2026
Aug 20, 2026Kurzius Lawrence ErikDirectoropen-market buy40,000$23.40$936K188,647Aug 21, 2026
Aug 18, 2026O'Neill ShivGC AND CORP SECopen-market buy3,998$23.58$94K87,832Aug 18, 2026
Aug 12, 2026Harrington Michael JDirectoropen-market buy5,000$21.82$109K131,451Aug 13, 2026
Aug 7, 2026VanHimbergen Robert MEVP and CFOopen-market buy4,200$23.08$97K137,516Aug 10, 2026
Aug 7, 2026Herendeen PaulDirectoropen-market buy10,000$23.68$237K111,687Aug 10, 2026
Jul 7, 2026VanHimbergen Robert MEVP and CFOtax withholding15,336$24.64$378K133,316Jul 9, 2026
May 21, 2026Scots-Knight DeniseDirectoraward4,678$0.00—93,392May 26, 2026
May 21, 2026Scots-Knight DeniseDirectoraward12,196$0.00—105,588May 26, 2026
May 21, 2026Kurzius Lawrence ErikDirectoraward4,678$0.00—136,451May 26, 2026
May 21, 2026Kurzius Lawrence ErikDirectoraward12,196$0.00—148,647May 26, 2026
May 21, 2026McDonald Kirk PDirectoraward4,678$0.00—93,392May 26, 2026
May 21, 2026McDonald Kirk PDirectoraward12,196$0.00—105,588May 26, 2026
May 21, 2026Herendeen PaulDirectoraward4,678$0.00—89,491May 26, 2026
May 21, 2026Herendeen PaulDirectoraward12,196$0.00—101,687May 26, 2026
May 21, 2026Kochevar Deborah TurnerDirectoraward4,678$0.00—94,392May 26, 2026
May 21, 2026Hoover R DavidDirectoraward4,678$0.00—111,451May 26, 2026
May 21, 2026Harrington Michael JDirectoraward4,678$0.00—114,255May 26, 2026
May 21, 2026Harrington Michael JDirectoraward12,196$0.00—126,451May 26, 2026
May 21, 2026Anand Kapila KDirectoraward4,678$0.00—99,651May 26, 2026
May 21, 2026Anand Kapila KDirectoraward12,196$0.00—111,847May 26, 2026
May 21, 2026Ma StaceyDirectoraward4,678$0.00—17,531May 26, 2026
May 21, 2026Ma StaceyDirectoraward12,196$0.00—29,727May 26, 2026
May 21, 2026Garcia Art ADirectoraward4,678$0.00—95,956May 26, 2026
May 21, 2026Garcia Art ADirectoraward12,196$0.00—108,152May 26, 2026

Full insider history for Elanco Animal Health Incorporated Common Stock, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held ELAN in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded ELAN by quarter.

FundManagerQuarterValueSharesWeightMove
Baron Capital GroupRon BaronQ2 2026$3M118,0390.00%trimmed −27.8%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Elanco Animal Health Incorporated, CIK 1739104 on EDGAR
Extract generated
November 4, 2026
Withheld
none
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: not filed
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: not filed
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: not filed
Dividends paid: not filed

The data

The statements on this page as files, generated November 4, 2026.

JSON file
/data/financials/ELAN.json